Drug Trial Radar · NCT06059222
The Optimised Use of Romozosumab Study
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Oct 2, 2023
Primary completion
Aug 31, 2030
Study completion Aug 31, 2032
Sponsor
- Lead sponsor
- University of AarhusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OPTIMIST is a two-year, randomised, active controlled, open-label, multicentre intervention trial. OPTIMIST includes 3 treatment groups each comprising combinations of romosozumab (ROMO) and zoledronate (ZOL) treatment used in standard doses (210 mg monthly (sc) and 5 mg yearly (iv), respectively). The study will investigate if it is possible to maximize the effect of romosozumab by giving it in 2 periods of 6 months interrupted by zoledronate for 12 months compared to romosozumab for 12 months uninterrupted followed by zoledronate for 12 months. The investigators will also evaluate if 6 months of romosozumab followed by 18 months of zoledronate is non-inferior to the standard regimen of romosozumab for 12 months followed by zoledronate for 12 months.
Conditions
- Osteoporosis
Interventions
RomosozumabDrug
Romosozumab 210 mg/2.34 ml from baseline to month 11
ZoledronateDrug
5 mg/100 ml at month 12
RomosozumabDrug
210 mg/2.34 ml from baseline to month 5 and from month 18 to month 23
ZoledronateDrug
5 mg/100 ml at month 6
RomosozumabDrug
210 mg/2.34 ml from baseline to month 5
ZoledronateDrug
5 mg/100 ml at month 5 and month 18
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in total hip BMDTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Endrocinology and Internal Medicine
Aarhus, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.